Proactive Investors - Run By Investors For Investors

Northland Capital Partners View on the City - Oxford Biodynamics PLC, Veltyco Group plc

Northland Capital Partners View on the City - Oxford Biodynamics PLC, Veltyco Group plc

OXFORD BIODYNAMICS PLC (LON:OBD)

SECTOR – HEALTHCARE

MARKET CAP – £209m

CURRENT PRICE – 242p#

Prospective study data presented at ALS disease conference

NORTHLAND VIEW

 Oxford BioDynamics presented prospective study data regarding its proprietary EpiSwitch™ technology at the 2017 Annual Northeast ALS Consortium (NEALS) Meeting in Florida.

 The prospective study measured the sensitivity and specificity of two epigenetic-based Amyotrophic Lateral Sclerosis (ALS) disease signatures and how they may assist in the diagnosis of ALS and the prognosis of fast versus slow progressing ALS.

 ALS is a progressive neurodegenerative disease, affecting nerve cells in the brain and spinal cord. There is currently no cure. 100 patients underwent clinical assessments and provided blood samples which were analyzed using the Company’s EpiSwitch™ technology.

 Comparisons between healthy volunteers and ALS patients revealed two ALS-related epigenetic signatures, with one signature having diagnostic potential whilst the other may aid prediction of prognosis.

 The diagnostic epigenetic signature had specificity of 75% and sensitivity of 88% whilst the prognostic test had specificity and sensitivity of 80%. 

Dr Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics, commented: “This prospective study has delivered two new and unique epigenetic biomarker signatures that have the potential to improve the time to diagnosis and provide a predictive prognosis for the progression of the disease. We look forward to further expanding our EpiSwitchTM ALS studies in close collaboration with leading clinical experts, both in US and UK.”

 

COMPANY DESCRIPTION

Oxford BioDynamics is a clinical stage biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture for use within the pharmaceutical and biotechnology industry.

 

VELTYCO GROUP (LON:VLTY)

SECTOR – LEISURE

RATING – BUY*

MARKET CAP – £65.4m

CURRENT PRICE – 88p#

TARGET PRICE – 110p

Esports.com partnership, accessing a US$500m online gaming market

 

NORTHLAND VIEW

 Veltyco Group has entered into a partnership agreement with Esports Radar Ltd., a newly-incorporated company in Malta focused to develop esports-based opportunities.  Esports Radar has established a wholly-owned subsidiary, Esports.com Ltd., to tap the potential of gaming based on the rapidly-developing enthusiasm for esports.  It owns the domain name www.esports.com. 

 Esport competition has developed around Playstation-, Xbox- and PC-based gaming. Esports.com aims to build an online community to produce content aimed at esports enthusiasts.  This will include esports merchandise, hardware or in-game items, licensed esports betting and user guides, tutorials and coaching. 

 Veltyco has taken a minority interest in Esports for a nominal consideration, and will use its Bet90 brand as the platform for the partnership and marketing its gaming products.

Veltyco recently reported strong interims – revenue +202% at €6.4m, EBITDA +410% at €3.8m – and is clearly aware of new opportunities such as the esports online gaming trend. 2017 global esports revenue is estimated at US$465m (source; gamesindustry.biz) backed by some 385m gamers and augmented by popular international tournaments, in 2015 the establishment of the first dedicated esports arena in Santa Ana and a major new venue planned at the Luxor in Las Vegas for 2018.

COMPANY DESCRIPTION

Veltyco is a marketing and promotions business which refers customers to online casino, sports betting, lotteries and options trading brands.

1. Northland Capital Partners Limited (“Northland”) acts as Nominated Advisor and/or Broker to the company.

2. Northland) and/or its affiliates companies do beneficially own 1% or more of any class of the issuer’s equity securities, as of the end of the month immediately preceding the date of issuance of the research report or the end of the second most recent month if the issue date is less than 10 calendar days after the end of the most recent month. 

3. The authoring analyst or any associate of the authoring analyst does maintain a long or short position in any of the issuer’s securities directly or through derivatives, including options or futures positions.

4. Northland, its affiliated companies, partners, officers, directors or any authoring analyst of Northland has provided services to the issuer for remuneration during the preceding 12 months other than investment advisory or trading services.

5. Northland or any of its affiliated companies has performed investment banking services for the issuer during the 12 months preceding the date of issuance of the report.  

6. A partner, director, officer, employee or agent of Northland or any of its affiliated companies is an officer, director, employee or advisor of the issuer.  Disclosures are applicable for all companies

7. The authoring analyst, or any associate of the authoring analyst, has viewed the material operations of the issuer. 

8. The authoring analyst, or any associate of the authoring analyst, received reimbursement for travel expenses.

9. Northland makes a market in the securities of this company.

 

 

DISCLAIMER

This document is provided solely to enable clients to make their own investment decisions. It may therefore not be suitable for all recipients and does not constitute a personal recommendation to invest. It does not constitute an offer or solicitation to buy or sell securities or instruments of any kind. If you have any doubts about the suitability of this service, you should seek advice from your investment adviser. This document is produced in accordance with UK laws and regulations. It is not intended for any person whose nationality or residential circumstances may render its receipt unlawful.

The past is not necessarily a guide to future performance. The value of shares and the income arising from them can fall as well as rise and investors may get back less than they originally invested. The information contained in this document has been obtained from sources which Northland Capital Partners Limited believes to be re¬li¬able. The Com¬pany does not warrant that such information is accurate or complete. All estimates and prospective figures quoted in this report are forecasts and not guaranteed. Opinions included in this report reflect the Company’s judgement at the date of publication and are subject to change without notice. If the investment(s) mentioned in this report are denominated in a currency different from the currency of the country in which the recipient is a resident, the recipient should be aware that fluctuations in exchange rates may have an adverse effect on the value of the investment(s). The listing requirements for securities listed on AIM or PLUS markets are less demanding, also trading in them may be less liquid than main markets.

Northland Capital Partners Limited and/or its officers, as¬sociated entities or clients may have a position, or other material interest, in any securities men¬tioned in this report. Northland Capital Partners Limited does not provide recommendations on securities of firms with which it has a corporate relationship. More information about our management of Conflicts of Interest, Investment Research Methodology & Definition of Recommendations can be found at www.northlandcp.co.uk 

Northland Capital Partners Limited is authorised and regulated by the Financial Conduct Authority and a Member of the London Stock Exchange.

Published by/copyright: Northland Capital Partners Limited, 2013. All rights reserved

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use